FOR IMMEDIATE RELEASE
Kuala Lumpur/ Singapore, 20 November 2019

IHH Healthcare Invests In Genomic Medicine Company to Provide Cancer Patients Better Treatment Outcomes

- Led minority investment in genomic medicine start-up Lucence
- Offers patients clinically validated blood-based cancer screening and treatment monitoring solutions with a focus on cancers commonly found in Asia
- Embraces value-based healthcare approach that aims to improve clinical outcomes through less invasive, more precise, and more affordable technology

IHH Healthcare (“IHH” or the “Group”), a leading premium global healthcare provider, led a minority investment in Singapore-based genomic medicine company Lucence as part of a USD $20 million Series A.

The investment is part of IHH’s collaboration with start-ups to deploy innovative and cutting-edge healthcare technology to enhance the patient experience, treatment and clinical outcomes across its network of 80 hospitals in 10 countries. In Singapore, for example, IHH is working with a local start-up to improve estimated bill size for patients ahead of admission through predictive AI.

The partnership with Lucence will give IHH patients access to Lucence’s suite of cancer diagnostics and AI-driven analytics. Lucence uses liquid biopsy, a blood-based technology that is less invasive than tissue biopsies, to help clinicians discover a range of information about a tumour and aid in their treatment decisions through a simple blood sample. It focuses on Asia-prevalent cancers such as lung, breast, colorectal, pancreatic, nasopharyngeal and liver cancers.

Dr Kelvin Loh, Chief Executive Officer (Designate) of IHH Healthcare, said, “Liquid biopsy is a game-changer in our endeavour to provide cancer patients with better, value-driven outcomes through precise treatment selections and more affordable care. Our investment in Lucence will provide IHH patients with better access to this advanced technology. IHH looks to drive greater synergies with Lucence and co-develop solutions for patients, as well as explore opportunities to sharpen our precision medicine capabilities with other like-minded partners across our 10-country network.”

Dr Min-Han Tan, founder and CEO of Lucence, said, "Our mission is to reduce worldwide suffering through early cancer detection. As a medical oncologist, I have worked in the clinic and the laboratory for over a decade, striving towards a world where cancer can be overcome with early screening. Our research discoveries, such as the identification of the circulating tumour-endothelial cluster, can transform the liquid biopsy field, allowing better non-invasive cancer screening and profiling for patients. This partnership with IHH Healthcare will accelerate more groundbreaking research to achieve early cancer
detection and effective cures, and expand access to this much-needed liquid biopsy technology to patients across Asia and the United States."

For further information or to speak to an IHH spokesperson, please contact:

Lim Bee Ling
t. +65 9765 0598
e. beeling.lim@parkwaypantai.com

Ong Chor Hao
t. +65 9627 2674
e. chorhaoo@we-watawawa.com

About IHH Healthcare Berhad

IHH Healthcare Berhad is a leading premium integrated healthcare provider in markets where the demand for quality care is strong and growing. We are one of the largest healthcare groups in the world by market capitalisation and are listed on the Main Market of Bursa Malaysia and the Main Board of SGX-ST.

Employing more than 55,000 people and operating over 15,000 licensed beds across 80 hospitals in 10 countries worldwide, the Group offers the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services across our operating subsidiaries:

- **Parkway Pantai Limited** is one of Asia’s largest integrated private healthcare groups with a network of 29 hospitals throughout the region, including Malaysia, Singapore, India, China and Brunei. Its “Mount Elizabeth”, “Gleneagles”, “Parkway” and “Pantai” brands are among the most prestigious in Asia.

- **Acibadem Holdings** is Turkey’s leading private healthcare provider, offering integrated healthcare services across 22 hospitals in Turkey, Macedonia, Bulgaria and Amsterdam. The “Acibadem” brand is renowned for its clinical excellence in the Central & Eastern Europe, Middle East and North Africa (“CEEMENA”) region.

- **Fortis Healthcare Limited** is a leading integrated private healthcare provider in India. It operates across a network of 29 hospitals and 400 diagnostic centres in India, Dubai and Sri Lanka. Fortis is listed on the National Stock Exchange of India Ltd and Bombay Stock Exchange.
• **IMU Health** is IHH’s medical education arm, and oversees the established higher learning institutions of International Medical College (“IMC”) and International Medical University (“IMU”) in Malaysia.

IHH is the leading player in our home markets of Malaysia, Singapore, Turkey and India, and key growth markets of China and Hong Kong. For more information, please visit [www.ihhhealthcare.com](http://www.ihhhealthcare.com).

**About Lucence**

Lucence is a genomic medicine company founded on a vision of a world without avoidable cancer deaths. The company develops non-invasive blood tests that achieve early cancer detection and improve treatment selection. Headquartered in Singapore with offices in San Francisco, Hong Kong, and Suzhou, its services are delivered worldwide through a CLIA-certified and CAP-accredited laboratory. For more information, please visit [www.lucencedx.com](http://www.lucencedx.com).